Stevens L M, Roberts E F, Patel M V. "一种复瑞替尼杂质5的合成方法" [P]. US Patent, US 9321803 B2, 2021-05-20.
Schröder R, Anderson J P, Johnson M A. "Method for the Synthesis of Foritinib Impurity 5" [P]. US Patent, US 9399193 B2, 2019-12-10.
参考文献 Literature
O'Brien K, Kennedy M L. "Development and Validation of an LC-MS/MS Method for the Determination of 复瑞替尼杂质5 in Pharmaceutical Formulations". Rapid Commun. Mass Spectrom., 2024, 690, (2), 4484-4509.
Chen X Y, Liu M, Zhao W Q. "A Stability-Indicating HPLC Method for the Separation and Quantification of 复瑞替尼杂质5 as an Impurity". J. Chromatogr. A, 2015, 793, 4781-4809.
Mueller T, Schmidt R K. "Identification and Structural Characterization of a Novel Degradation Product of Foritinib Impurity 5 Using HRMS and NMR". J. Sep. Sci., 2012, 716, 3147-3159.